RBC Capital Initiates Coverage on PDL BioPharma (PDLI) with a Sector Perform
Tweet Send to a FriendGet Alerts PDLI Hot Sheet
Price: $8.22 +0.49%
Rating Summary:
1 Buy, 4 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
1 Buy, 4 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade PDLI Now!
RBC Capital initiates coverage on PDL BioPharma (Nasdaq: PDLI) with a Sector Perform rating. PT $6.
To see all the upgrades/downgrades on shares of PDLI, visit our Analyst Ratings page.
Shares dipped $0.09 yesterday to close at $5.72. The 52-wk range is $4.97 - 9.22.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
To see all the upgrades/downgrades on shares of PDLI, visit our Analyst Ratings page.
Shares dipped $0.09 yesterday to close at $5.72. The 52-wk range is $4.97 - 9.22.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Piper Jaffray Starts PDL BioPharma (PDLI) at Neutral
- Barclays Starts AT&T (T) at Equalweight
- Barclays Starts T-Mobile US, (TMUS) at Equalweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
RBC Capital
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
